Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
INTRODUCTION
Several removable or fixed functional appliances are
used for treatment of Class II division 1 malocclusions
with mandibular deficiency in order to stimulate
mandibular growth by forward positioning of the mandible. Unlike removable functional appliances, fixed
functional devices have the advantage of not requiring
patient compliance, and they can also be used
concurrently with brackets.1
a
Research Assistant, Gazi University, Faculty of Dentistry,
Department of Orthodontics, Ankara, Turkey.
b
Assistant Professor, Gazi University, Faculty of Dentistry,
Department of Orthodontics, Ankara, Turkey.
c
Professor, Gazi University, Faculty of Dentistry, Department
of Orthodontics, Ankara, Turkey.
Corresponding author: Dr Belma I. Aslan, Research Assistant,
Department of Orthodontics, Faculty of Dentistry, University of
Gazi, 06510 Emek, Ankara, Turkey
(e-mail: belmaslan2003@yahoo.com)
76
DOI: 10.2319/032613-240.1
77
Treatment Methods
Fixed Roth appliances with 0.018-inch slots were
attached. In the FRDMS group, mandibular canines
78
Figure 3. Before and after lateral cephalograms and photos of a patient in the FRDMS group.
Figure 4. Skeletal measurements on lateral cephalograms. VRL indicates vertical reference line, which is perpendicular to the HRL. HRL
indicates horizontal reference line constructed by drawing a line having a 7u difference with the SN plane. 1: SN (mm); 2: SNA (u); 3: A-VRL (mm);
4: FH/NA (u); 5: SN/ANSPNS (u); 6: SNB (u); 7: B-VRL (mm); 8: Pog-VRL (mm); 9: Ar-Pog (mm); 10: FH/NPog (u); 11: ANB (u); 12: N-A-Pog (u);
13: N-Me (mm); 14: ANS-Me (mm); 15: S-Go (mm); 16: SN/GoGn (u); 17: Ar-Go-Me (u); 18: ANSPNS/GoMe (u).
Angle Orthodontist, Vol 84, No 1, 2014
79
Figure 5. Dental and soft tissue measurements on lateral cephalograms. 1: SN/OP (u); 2: U1/L1 (u); 3: Overjet (mm); 4: Overbite (mm); 5: LbsupVRL (mm); 6: Lbinf-VRL (mm); 7: Pog-VRL (mm); 8: Labiomental angle (u).
(Orthophos XG5/Ceph; Sirona Gmbh, Salzburg, Germany). Initial and final radiograms of each patient were
traced manually at the same time and superimposed
on acetate paper by only one examiner to minimize
any method error. The cephalometric landmarks and
skeletal, dental, and soft tissue measurements are
illustrated in Figures 46. The perpendicular to a
constructed horizontal line, 7u to SN plane, was taken
as the reference plane. The reference lines used in this
study were also used in previous investigations.10,12
Statistical Method
Data analysis was performed by using the Statistical
Package for Social Sciences version 22.0 software
(SPSS Inc, Chicago, Ill). Shapiro-Wilk test was
performed to verify normal distribution of the data.
Data were expressed as the mean 6 standard
deviation. Whether the differences between pre-and
posttreatment measurements (intragroup) were statistically significant was evaluated by a Bonferroniadjusted paired-samples t-test. The differences between groups were compared with a one-way analysis
of variance test. If a statistically significant difference
was found, a Tukey multiple-comparison test was used
Angle Orthodontist, Vol 84, No 1, 2014
80
Figure 6. Horizontal, vertical, and angular measurements of the maxillary and mandibular incisor and molars related to the reference lines. 1: U6VRL (mm); 2: U6-HRL (mm); 3: U6/HRL (u); 4: U1-VRL (mm); 5: U1-HRL (mm); 6: U1/HRL (u); 7: L1-VRL (mm); 8: L1-GoMe (mm); 9: L1/GoMe
(u); 10: L6-VRL (mm); 11: L6-GoMe (mm); 12: L6/GoMe (u); 13: Molar relationship (mm).
RESULTS
Appliance breakage was observed in two patients
(one with FRDMS, the other with FRD), and mobility of
miniscrews during FRD application was determined
bilaterally in another two patients, in which cases
appliances and miniscrews were replaced. Differences
Angle Orthodontist, Vol 84, No 1, 2014
81
SN, mm
SNA, u
A-VRL, mm
FH/NA, u
SN/ANSPNS, u
SNB, u
B-VRL, mm
Pog-VRL, mm
Ar-Pog, mm
FH/NPog, u
ANB, u
N-A-Pog, u
N-Me, mm
ANS-Me, mm
S-Go, mm
SN/GoGn, u
Ar-Go-Me, u
ANSPNS/GoMe, u
U6-VRL, mm
U6-HRL, mm
U6/HRL, u
L6-VRL, mm
L6-MP, mm
L6/MP, u
U1-VRL, mm
U1-HRL, mm
U1/HRL, u
L1-VRL, mm
L1-MP, mm
L1/MP, u
SN/OP, u
U1/L1, u
OJ, mm
OB (mm)
Molar rel., mm
Lbsup-VRL, mm
Lbinf-VRL, mm
Pog-VRL, mm
Labiomental, u
a
ICC
P value
Difference Mean
Difference SD
Repeatability
0.99
0.99
1.00
0.99
0.99
1.00
1.00
1.00
0.99
0.99
1.00
1.00
0.99
1.00
1.00
0.99
0.99
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
0.99
1.00
0.99
0.99
1.00
1.00
1.00
1.00
1.00
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
,.001
0.08
0.03
0.05
20.06
0.06
0.00
0.00
0.00
0.02
20.04
0.01
20.02
0.18
0.04
0.07
0.13
0.13
0.04
0.00
0.01
0.00
20.01
0.00
0.01
0.02
0.01
20.03
0.00
20.02
0.00
20.03
0.14
20.05
20.05
0.00
0.00
0.00
0.01
20.23
0.19
0.18
0.09
0.20
0.28
0.00
0.00
0.00
0.18
0.14
0.05
0.08
0.21
0.19
0.14
0.20
0.27
0.13
0.00
0.05
0.00
0.05
0.00
0.09
0.07
0.05
0.22
0.00
0.14
0.00
0.12
0.23
0.14
0.11
0.00
0.00
0.00
0.05
0.59
0.54
0.50
0.25
0.56
0.78
0.00
0.00
0.00
0.49
0.38
0.14
0.21
0.59
0.52
0.39
0.56
0.75
0.36
0.00
0.14
0.00
0.14
0.00
0.25
0.21
0.14
0.61
0.00
0.38
0.00
0.29
0.62
0.39
0.30
0.00
0.00
0.00
0.14
1.64
82
Table 2. The Initial Mean Values of Skeletal, Dental, and Soft Tissue Parameters, Age, and Treatment/Control Duration in Each Group and
Significance Values of the Differences Between FRDMS (1), FRD (2), and Control (3) Groupsa
1 (n 5 16)
SN, mm
SNA, u
A-VRL, mm
FH/NA, u
SN/ANSPNS, u
SNB, mm
B-VRL, mm
Pog-VRL, mm
Ar-Pog, mm
FH/NPog, u
ANB, u
N-A-Pog, u
N-Me, mm
ANS-Me, mm
S-Go, mm
SN/GoGn, u
Ar-Go-Me, u
ANSPNS/GoMe, u
U6-VRL, mm
U6-HRL, mm
U6/HRL, u
L6-VRL, mm
L6-MP, mm
L6/MP, u
U1-VRL, mm
U1-HRL, mm
U1/HRL, u
L1-VRL, mm
L1-MP, mm
L1/MP, u
SN/OP, u
OJ, mm
OB, mm
U1/L1, u
Molar Rel, mm
LbSup-VRL, mm
Lbinf-VRL, mm
Pog-VRL, mm
Labiomental, u
Chronological age, y
Skeletal age, y
Treatment duration, mo
74.70
80.53
70.03
89.57
8.46
74.81
58.84
59.50
107.26
85.19
5.71
9.46
121.34
66.84
80.81
31.84
122.90
25.89
37.26
65.62
77.93
35.20
28.71
76.84
74.81
75.75
112.03
68.00
43.26
98.53
15.34
7.31
4.54
122.96
2.06
88.00
78.50
71.53
110.66
13.68
13.50
6.50
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
3.70
3.76
3.50
2.53
2.23
2.51
4.69
6.06
6.19
2.51
2.28
5.82
5.79
4.20
4.43
3.84
5.64
4.84
4.04
3.38
5.40
3.90
2.34
5.15
4.77
4.33
5.11
3.98
2.24
5.42
3.23
2.43
2.10
9.00
1.96
4.24
4.19
5.12
17.67
1.09
1.25
1.97
2 (n 5 17)
76.87
78.27
72.32
87.70
9.23
73.97
61.55
63.00
110.35
85.61
4.30
6.60
124.11
67.52
83.85
29.41
123.52
23.00
39.07
68.68
79.55
36.35
28.29
76.94
75.58
79.33
110.17
68.91
43.01
96.61
14.55
6.52
5.29
127.38
2.71
91.08
82.94
76.17
100.67
14.64
14.34
5.50
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
3.13
2.19
3.72
2.71
3.03
2.57
5.78
6.94
5.83
2.32
2.38
5.95
6.17
4.68
7.26
4.90
9.52
6.37
4.09
4.59
3.65
4.59
2.87
4.67
4.76
4.28
5.31
4.66
2.47
8.38
3.75
1.95
1.92
10.23
1.61
5.77
5.14
7.08
10.17
1.56
1.85
1.80
3 (n 5 15)
74.66
78.14
69.54
88.16
9.57
74.18
57.66
59.50
107.96
86.78
3.95
5.82
121.93
65.46
81.78
30.05
121.70
21.14
35.79
65.58
76.38
33.36
29.30
79.90
67.82
77.93
95.55
64.10
42.14
92.07
13.95
4.41
5.28
147.45
2.43
84.63
81.70
72.44
106.73
14.13
14.25
5.60
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
3,46
3.02
3.29
2.73
3.72
1.90
4.53
5.86
6.16
2.84
2.55
5.30
6.70
5.66
4.21
5.57
7.39
5.10
4.36
3.46
4.76
4.09
2.47
5.37
4.84
6.16
9.62
4.14
2.87
6.39
4.50
1.95
2.91
12.49
1.44
4.84
5.04
4.54
18.69
1.50
1.75
2.19
P
.082
.067
.079
.124
.465
.577
.051
.052
.060
.216
.053
.070
.066
.800
.069
.518
0,797
.063
.071
.062
.107
.056
.133
.0174
,.001*
.125
,.001*
,.001*
.057
.002*
.216
.001*
.586
,.001*
.325
.003*
.058
.062
.205
.061
.087
.340
P (12)
P (13)
P (23)
*
*
*
*
*
*
a
FRD indicates fatigue resistant device; FRDMS, FRD treatment used with miniscrew anchorage. Values for groups 1, 2, and 3 are expressed
as the mean 6 the standard deviation.
* P , .01; one-way analysis of variance.
83
Table 3. Mean Values and 95% Confidence Intervals of Parameters at the Beginning (T1) and End (T2) of FRD Application in the FRDMS
Group and Significance Values of Differences (T2-T1)a
FRDMS Group
T1
SN, mm
SNA, u
A-VRL, mm
FH/NA, u
SN/ANSPNS, u
SNB, u
B-VRL, mm
Pog-VRL, mm
Ar-Pog, mm
FH/NPog, u
ANB, u
N-A-Pog, u
N-Me, mm
ANS-Me, mm
S-Go, mm
SN/GoGn, u
Ar-Go-Me, u
ANSPNS/GoMe, u
U6-VRL, mm
U6-HRL, mm
U6/HRL, u
L6-VRL, mm
L6-MP, mm
L6/MP, u
U1-VRL, mm
U1-HRL, mm
U1/HRL, u
L1-VRL, mm
L1-MP, mm
L1/MP, u
SN/OP, u
U1/L1, u
OJ, mm
OB, mm
Molar Rel., mm
Lbsup-VRL, mm
Lbinf-VRL, mm
Pog-VRL, mm
Labiomental, u
74.70
80.53
70.03
89.57
8.46
74.81
58.84
59.50
107.26
85.19
5.71
9.46
121.34
66.84
80.81
31.84
122.90
25.89
37.26
65.62
77.93
35.20
28.71
76.84
74.81
75.75
112.03
68.00
43.26
98.53
15.34
122.96
7.31
4.54
2.06
88.00
81.70
71.53
110.66
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
3.70
3.76
3.50
2.53
2.23
2.51
4.69
6.06
6.19
2.51
2.28
5.82
5.79
4.20
4.43
3.84
5.64
4.84
4.04
3.38
5.40
3.90
2.34
5.15
4.77
4.33
5.11
3.98
2.24
5.42
3.23
9.00
2.43
2.10
1.96
4.24
5.04
5.12
17.67
(73.16,
(78.24,
(67.99,
(88.06,
(7.15,
(73.51,
(56.63,
(57.03,
(104.24,
(84.11,
(4.29,
(6.52,
(118.07,
(64.25,
(78.64,
(29.44,
(119.37,
(22.90,
(34.92,
(64.06,
(74.98,
(33.23,
(27.35,
(74.06,
(71.95,
(73.48,
(108.85,
(65.82,
(41.91,
(95.28,
(13.34,
(119.00,
(5.78,
(3.37,
(0.83,
(85.65,
(78.90,
(68.69,
(100.88,
76.46)
82.49)
72.00)
90.95)
9.71)
76.34)
61.76)
62.86)
110.81)
86.76)
.56)
12.41)
124.72)
68.94)
83.55)
33.49)
125.35)
28.27)
39.56)
67.73)
81.15)
37.59)
30.04)
79.93)
77.38)
78.38)
114.47)
70.37)
44.46)
101.45)
16.92)
128.59)
8.34)
5.78)
2.83)
90.34)
84.49)
74.37)
120.45)
T2
75.14
80.04
70.15
89.23
8.88
74.63
58.81
59.66
108.31
85.14
5.40
9.10
123.59
68.65
82.34
32.55
123.23
25.88
35.15
65.62
75.40
36.59
30.15
77.14
71.65
77.76
103.09
69.09
42.53
102.14
19.00
126.68
3.03
3.01
21.43
87.60
81.93
71.10
118.80
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
2.84
3.94
4.08
2.88
2.07
2.52
4.97
5.27
4.96
2.31
2.15
5.10
5.87
4.31
425
3.44
5.56
4.51
4.56
3.68
7.85
4.25
2.56
5.44
4.42
4.02
4.52
4.36
2.66
8.17
3.03
9.67
1.43
1.89
1.69
4.59
5.29
6.02
13.07
(73.68,
(77.61,
(67.76,
(87.48,
(7.68,
(73.13,
(56.05,
(56.84,
(105.56,
(83.95,
(4.06,
(6.27,
(120.23,
(65.98,
(79.92,
(30.43,
(119.74,
(23.17,
(32.63,
(64.14,
(72.22,
(34.09,
(28.56,
(73.76,
(68.98,
(75.57,
(100.47,
(66.42,
(40.98,
(97.02,
(17.11,
(122.39,
(2.34,
(2.17,
(22.19,
(85.05,
(79.00,
(67.76,
(111.55,
76.87)
82.00)
72.43)
90.74)
10.05)
76.02)
61.74)
62.84)
111.23)
86.55)
6.40)
11.92)
126.96)
70.75)
84.80)
34.27)
125.54)
28.29)
37.85)
67.92)
80.31)
38.96)
31.41)
79.76)
74.01)
80.16)
105.65)
71.31)
44.03)
105.67)
20.12)
132.73)
3.91)
4.20)
20.37)
90.14)
84.86)
74.43)
126.04)
P
.006*
.074
.633
.313
.052
.498
.940
.486
.070
.882
.312
.468
,.001*
,.001*
.002*
.042
.300
.983
,.001*
1.000
.046
.022
.001*
.686
,.001*
,.001*
.001*
.025
.056
.012
,.001*
.037
,.001*
.001*
,.001*
.429
.679
.427
.012
a
Values for T1 and T2 are the mean 6 the standard deviation. FRD indicates fatigue resistant device; FRDMS, FRD treatment used with
miniscrew anchorage; CI, confidence interval.
* P , .01; paired-sample t-test.
84
Table 4. Mean Values and 95% Confidence Intervals of Parameters at the Beginning (T1) and End (T2) of FRD Application in the FRD Group
and Significance Values of Differences (T2-T1)a
FRD Group
T1
SN, mm
SNA, u
A-VRL, mm
FH/NA, u
SN/ANSPNS, u
SNB, u
B-VRL, mm
Pog-VRL, mm
Ar-Pog, mm
FH/NPog, u
ANB, u
N-A-Pog, u
N-Me, mm
ANS-Me, mm
S-Go, mm
SN/GoGn, u
Ar-Go-Me, u
ANSPNS/GoMe, u
U6-VRL, mm
U6-HRL, mm
U6/HRL, u
L6-VRL, mm
L6-MP, mm
L6/MP, u
U1-VRL, mm
U1-HRL, mm
U1/HRL, u
L1-VRL, mm
L1-MP, mm
L1/MP, u
SN/OP, u
U1/L1, u
OJ, mm
OB, mm
Molar Rel., mm
Lbsup-VRL, mm
Lbinf-VRL, mm
Pog-VRL, mm
Labiomental, u
76.87
78.27
72.32
87.70
9.23
73.97
61.55
63.00
110.35
85.61
4.30
6.60
124.11
67.52
83.85
29.41
123.52
23.00
39.07
68.68
79.55
36.35
28.29
76.94
75.58
79.33
110.17
68.91
43.01
96.61
14.55
127.38
6.52
5.29
2.71
91.08
82.94
76.17
100.67
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
3.13
2.19
3.72
2.71
3.03
2.57
5.78
6.94
5.83
2.32
2.38
5.95
6.17
4.68
7.26
4.90
9.52
6.37
4.09
4.59
3.65
4.59
2.87
4.67
4.76
4.28
5.31
4.66
2.47
8.38
3.75
10.23
1.95
1.92
1.61
5.77
5.14
7.08
10.17
(76.26,
(77.14,
(70.40,
(86.31,
(7.67,
(72.64,
(58.58,
(59.42,
(107.35,
(84.42,
(3.18,
(3.85,
(120.94,
(65.12,
(80.11,
(26.88,
(118.63,
(19.72,
(36.96,
(66.32,
(77.68,
(33.99,
(26.81,
(74.53,
(73.13,
(77.13,
(107.44,
(66.51,
(41.74,
(92.30,
(12.62,
(122.11,
(5.52,
(4.30,
(1.88,
(88.11,
(80.29,
(72.53,
(95.44,
79.48)
79.40)
74.23)
89.09)
10.79)
75.29)
64.53)
66.57)
113.35)
86.81)
5.41)
9.45)
127.29)
69.93)
87.58)
31.93)
128.42)
26.27)
41.17)
71.04)
81.43)
38.71)
29.77)
79.34)
78.03)
81.53)
112.91)
71.31)
44.28)
100.92)
16.48)
132.64)
7.53)
6.28)
3.55)
94.05)
85.58)
79.81)
105.90)
T2
77.33
78.18
72.39
87.44
9.64
73.94
61.80
62.91
111.26
85.32
4.18
6.67
125.39
68.70
85.11
29.61
123.36
22.55
37.61
68.05
75.63
38.30
29.82
80.17
73.79
80.10
107.50
71.24
41.55
105.91
18.33
121.29
2.45
2.61
20.67
90.67
84.41
76.76
115.23
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
3.12
2.33
3.76
2.45
3.54
2.60
6.20
7.36
6.01
2.48
1.75
5.14
6.27
5.22
7.45
4.61
9.83
6.33
4.03
4.69
3.61
4.43
2.47
5.01
5.01
4.65
6.15
4.26
2.49
8.58
3.79
9.05
1.56
1.78
1.42
6.27
5.20
7.59
18.11
(76.72,
(76.98,
(70.46,
(86.17,
(7.82,
(72.59,
(58.61,
(59.12,
(108.17,
(84.04,
(3.28,
(4.03,
(122.17,
(66.02,
(81.28,
(27.24,
(118.30,
(19.29,
(35.54,
(65.64,
(73.77,
(36.02,
(28.55,
(77.59,
(71.21,
(77.71,
(104.33,
(69.05,
(40.27,
(101.49,
(16.38,
(116.63,
(1.64,
(1.69,
(21.40,
(87.44,
(81.73,
(72.85,
(105.92,
79.94)
79.38)
74.32)
88.70)
11.47)
75.28)
64.99)
66.69)
114.35)
86.59)
5.09)
9.32)
128.61)
71.39)
88.95)
31.99)
128.42)
25.81)
39.69)
70.47)
77.49)
40.58)
31.09)
82.75)
76.37)
82.49)
110.66)
73.43)
42.84)
110.32)
20.28)
125.94)
3.25)
3.52)
0.05)
93.90)
87.08)
80.66)
124.54)
.039
.511
.793
.269
.222
.881
.537
.825
.129
.181
.608
.890
.029
.013
.004*
.499
.724
.362
,.001*
.046
,.001*
,.001*
.001*
.002*
.001*
.003*
.029
,.001*
,.001*
,.001*
,.001*
,.001*
,.001*
,.001*
,.001*
.324
.003*
.286
,.001*
a
Values for T1 and T2 are the mean 6 the standard deviation. FRD indicates fatigue resistant device; CI, confidence interval.
* P , .01; paired-sample t-test.
85
Table 5. Mean Values and 95% Confidence Intervals of Parameters at the Beginning (T1) and End (T2) of the Observation Period in the Control
Group and Significance Values of Differences (T2-T1)
Control Group
T1
SN, mm
SNA, u
A-VRL, mm
FH/NA, u
SN/ANSPNS, u
SNB, u
B-VRL, mm
Pog-VRL, mm
Ar-Pog, mm
FH/NPog, u
ANB, u
N-A-Pog, u
N-Me, mm
ANS-Me, mm
S-Go, mm
SN/GoGn, u
Ar-Go-Me, u
ANSPNS/GoMe, u
U6-VRL, mm
U6-HRL, mm
U6/HRL, u
L6-VRL, mm
L6-MP, mm
L6/MP, u
U1-VRL, mm
U1-HRL, mm
U1/HRL, u
L1-VRL, mm
L1-MP, mm
L1/MP, u
SN/OP, u
U1/L1, u
OJ, mm
OB, mm
Molar Rel., mm
Lbsup-VRL, mm
Lbinf-VRL, mm
Pog-VRL, mm
Labiomental, u
74.66
78.14
69.54
88.16
9.57
74.18
57.66
59.50
107.96
86.78
3.95
5.82
121.93
65.46
81.78
30.05
121.70
21.14
35.79
65.58
76.38
33.36
29.30
79.90
67.82
77.93
95.55
64.10
42.14
92.07
13.95
147.45
4.41
5.28
2.43
84.63
78.50
72.44
106.73
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
3.46
3.02
3.29
2.73
3.72
1.90
4.53
5.27
6.16
2.84
2.55
5.30
6.70
5.66
4.21
5.57
7.39
5.10
4.36
3.46
4.76
4.09
2.47
5.37
4.84
6.16
9.62
4.14
2.87
6.39
4.50
12.49
1.95
2.91
1.44
4.84
4.19
4.54
18.69
(72.74,
(76.46,
(67.71,
(86.64,
(7.51,
(73.13,
(55.14,
(56.57,
(104.80,
(85.20,
(2.72,
(3.13,
(118.22,
(62.32,
(79.45,
(26.96,
(117.60,
(18.31,
(33.39,
(63.66,
(73.74,
(31.09,
(27.92,
(76.92,
(65.14,
(74.52,
(90.22,
(61.80,
(40.55,
(88.53,
(11.45,
(140.53,
(3.33,
(3.66,
(1.65,
(81.94,
(76.17,
(69.92,
(96.38,
76.58)
79.81)
71.37)
89.67)
11.63)
75.23)
60.17)
62.42)
111.22)
88.35)
5.17)
8.40)
125.64)
68.59)
84.12)
33.14)
125.79)
23.96)
38.08)
67.49)
79.02)
35.63)
30.67)
82.87)
70.51)
81.34)
100.88)
66.39)
43.73)
95.61)
16.45)
154.37)
5.49)
6.89)
3.25)
87.31)
80.82)
74.96)
117.08)
T2
75.20
78.10
69.80
88.11
9.66
74.28
58.12
59.66
109.00
86.52
3.82
5.45
123.24
66.36
82.64
30.25
121.76
21.32
36.11
66.50
76.18
33.93
29.68
80.10
68.18
78.91
95.68
64.40
42.88
91.47
13.68
147.47
4.44
5.38
2.18
85.01
78.90
72.86
105.23
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
3.31
3.13
3.37
2.75
3.69
2.29
5.02
5.89
5.93
3.27
1.75
4.24
7.64
6.36
4.28
5.96
7.53
5.84
4.32
3.80
4.41
4.01
2.79
4.46
4.70
6.64
9.45
4.46
3.13
6.82
4.85
13.50
1.91
3.07
1.40
5.06
4.50
4.88
20.91
(73.36,
(76.36,
(67.93,
(86.58,
(7.61,
(73.01,
(55.33,
(56.39,
(105.71,
(84.71,
(2.85,
(3.10,
(119.00,
(62.84,
(80.26,
(26.95,
(117.59,
(18.09,
(33.71,
(64.39,
(73.73,
(31.71,
(28.13,
(77.62,
(65.57,
(75.23,
(90.44,
(61.92,
(41.14,
(87.69,
(10.99,
(139.99,
(3.37,
(3.68,
(1.40,
(82.20,
(76.40,
(70.16,
(93.64,
76.03)
79.84)
71.66)
89.64)
11.70)
75.54)
60.90)
63.07)
112.28)
88.33)
4.80)
7.80)
127.47)
69.88)
85.01)
33.55)
125.93)
24.56)
38.51)
68.60)
78.62)
36.15)
31.22)
82.57)
70.78)
82.59)
100.91)
66.87)
44.61)
95.25)
16.36)
154.95)
5.50)
7.09)
2.95)
87.81)
81.39)
75.57)
116.81)
P
.008*
.832
.28
.750
.74
.685
.441
.486
.017
.357
.501
.405
.006*
.005*
.060
.491
.872
.603
.291
.014
.784
.145
.069
.809
.351
.001*
.834
.432
.002*
.338
.648
.980
.908
.400
.036
.487
.489
.450
.583
a
Values for T1 and T2 are the mean 6 the standard deviation. CI indicates confidence interval.
* P , .01; paired-sample t-test.
86
Table 6. The Mean Differences (T2-T1) and 95% Confidence Intervals of Skeletal Parameters in Each Group and Significance Values of the
Differences Between FRDMS (1), FRD (2), and Control (3) Groupsa
1
SN, mm
SNA, u
A-VRL, mm
FH/NA, u
SN/ANSPNS, u
SNB, mm
B-VRL, mm
Pog-VRL, mm
Ar-Pog, mm
FH/NPog, u
ANB, u
N-A-Pog, u
N-Me, mm
ANS-Me, mm
S-Go, mm
SN/GoGn, u
Ar-Go-Me, u
ANSPNS/GoMe, u
0.44
20.49
0.13
20.34
0.42
20.17
20.03
0.17
1.05
20.05
20.31
20.36
2.25
1.81
1.53
0.71
0.33
20.01
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
0.54
1.01
1.02
1.31
0.86
1.00
1.63
1.85
2.14
1.32
1.19
1.90
1.94
1.54
1.67
1.27
1.21
1.13
(0.16,
(21.11,
(20.48,
(21.14,
(20.06,
(20.76,
(21.01,
(20.92,
(20.28,
(20.88,
(20.83,
(21.42,
(1.09,
(0.89,
(0.52,
(0.29,
(20.41,
(20.40,
0.77)
0.01)
0.68)
0.34)
0.93)
0.06)
0.41)
0.61)
2.12)
0.50)
0.43)
0.68)
3.31)
2.65)
2.01)
1.49)
0.97)
0.70)
0.46
20.08
0.07
20.26
0.41
20.03
0.25
20.09
0.91
20.29
20.11
0.07
1.28
1.18
1.26
0.21
20.16
20.44
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
0.85
0.50
1.08
0.95
1.33
0.80
1.61
1.62
2.34
0.86
0.88
2.24
2.18
2.25
1.79
1.14
1.89
1.94
(0.03,
(20.34,
(20.49,
(20.76,
(20.28,
(20.44,
(20.58,
(20.92,
(20.29,
(20.74,
(20.57,
(21.07,
(0.15,
(0.02,
(0.34,
(20.38,
(21.14,
(21.44,
0.90)
0.18)
0.63)
0.23)
1.10)
0.38)
1.08)
0.75)
2.12)
0.15)
0.34)
1.23)
2.40)
2.34)
2.19)
0.80)
0.81)
0.56)
0.53
20.03
0.25
20.05
0.09
0.09
0.46
0.31
1.03
20.25
20.13
20.36
1.31
0.91
0.85
0.20
0.07
0.19
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
0.66
0.59
0.82
0.55
0.99
0.87
1.65
1.69
1.48
1.02
0.71
1.65
1.56
1.04
1.61
1.09
1.58
1.35
(0.16,
(20.36,
(20.20,
(20.35,
(20.46,
(20.39,
(20.46,
(20.63,
(0.21,
(20.82,
(20.52,
(21.28,
(0.44,
(0.33,
(20.04,
(20.41,
(20.81,
(20.57,
0.90)
0.30)
0.71)
0.26)
0.64)
0.58)
1.38)
1.25)
1.85)
0.32)
0.27)
0.54)
2.17)
1.48)
1.75)
0.81)
0.94)
0.94)
P
P
P
(12) (13) (23)
.071
.345
.869
.655
.630
.707
.705
.809
.529
.792
.507
.571
.148
.103
.546
.383
.679
.495
FRD indicates fatigue resistant device; FRDMS, FRD treatment used with miniscrew anchorage; CI, confidence interval. Values for groups 1,
2, and 3 are expressed as the mean distance 6 the standard deviation.
* P , .01; one-way analysis of variance.
Table 7. The Mean Differences (T2-T1) and 95% Confidence Intervals of Dentoalveolar and Soft Tissue Parameters in Each Group and
Significance Values of the Differences Between FRDMS (1), FRD (2), and Control (3) Groupsa
1
U6-VRL, mm 22.11
U6-HRL, mm 0.00
U6/HRL, u
22.53
L6-VRL, mm 1.39
L6-MP, mm
1.43
L6/MP, u
0.30
U1-VRL, mm 23.16
U1-HRL, mm 2.01
U1/HRL, u
28.94
L1-VRL, mm 1.09
L1-MP, mm 20.73
L1/MP, u
3.61
SN/OP, u
3.66
U1/L1, u
3.72
OJ, mm
24.28
OB, mm
21.53
Molar Rel, 23.50
mm
LbSup-VRL, 20.40
mm
Lbinf-VRL,
0.23
mm
Pog-VRL,
20.43
mm
Labiomental, u 8.13
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
1.66
1.28
4.66
1.83
1.40
2.91
1.90
1.79
5.70
1.76
1.41
5.07
3.24
6.51
2.15
1.19
2.06
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
95% CI
0.83
1.20
3.34
1.33
1.46
3.19
1.90
0.91
4.43
1.68
1.27
3.81
3.33
4.42
2.02
1.52
1.72
(21.88,
(21.25,
(25.64,
(1.27,
(0.78,
(1.59,
(22.77,
(0.30,
(24.95,
(1.47,
(22.11,
(7.33,
(2.06,
(28.36,
(25.12,
(23.46,
(24.28,
21.02)
20.01)
22.20)
2.64)
2.28)
4.88)
20.81)
1.24)
20.40)
3.20)
20.80)
11.25)
5.49)
23.82)
23.03)
21.90)
22.51)
3
0.32
0.92
20.21
0.57
0.38
0.20
0.35
0.98
0.13
0.30
0.73
20.60
20.27
0.02
0.03
0.11
20.41
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
1.13
1.24
2.86
1.42
0.74
3.13
1.41
0.93
2.29
1.43
0.72
2.34
2.26
3.01
0.87
0.47
0.69
95% CI
(20.32, 0.95)
(0.23, 1.61)
(21.79, 1.38)
(20.22, 1.35)
(20.03, 0.79)
(21.54, 1.94)
(20.43, 1.14)
(0.46, 1.50)
(21.15, 1.40)
(20.50, 1.10)
(0.33, 1.14)
(21.90, 0.70)
(21.53, 0.98)
(21.65, 1.69)
(20.46, 0.51)
(20.16, 0.37)
(20.80, 20.03)
,.001*
.003*
.024
.054
.026
.010*
,.001*
.063
,.001*
.004*
,.001*
,.001*
.000*
,.001*
,.001*
,.001*
,.001*
20.41 6 1.67
(21.27, 0.44)
0.38 6 2.06
(20.76, 1.52)
.415
1.47 6 1.77
(0.55, 2.38)
0.40 6 2.18
(20.80, 1.60)
.115
0.59 6 2.19
(20.54, 1.71)
0.42 6 1.90
(20.63, 1.47)
.343
6 10.94
.001*
P
(12)
P
(13)
*
*
*
*
*
*
*
*
*
*
*
*
*
*
P
(23)
*
*
*
*
*
*
*
*
*
*
*
FRD indicates fatigue resistant device; FRDMS, FRD treatment used with miniscrew anchorage; CI, confidence interval. Values for groups 1,
2, and 3 are expressed as the mean distance 6 the standard deviation.
* P , .01; one-way analysis of variance.
Angle Orthodontist, Vol 84, No 1, 2014
87
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
CONCLUSIONS
N Overjet and molar correction was totally dentoalveolar in both treatment groups.
N Usage of miniscrews during FRD application was
effective in minimizing labial tipping of mandibular
incisors when miniscrews stay stable during treatment.
16.
17.
18.
REFERENCES
1. OBrien K, Wright J, Conboy F, et al. Effectiveness of
treatment for Class II malocclusion with the Herbst or Twinblock appliances: a randomized, controlled trial. Am J Orthod
Dentofacial Orthop. 2003;124:128137.
2. Ruf S, Pancherz H. Herbst/multibracket appliance treatment of Class II Division 1 malocclusions in early and late
adulthood. A prospective cephalometric study of consecutively treated subjects. Eur J Orthod. 2006;28:352360.
3. Pangrazio-Kulbersh V, Berger JL, Chermak DS, Kaczynski
R, Simon ES, Haerian A. Treatment effects of the
mandibular anterior repositioning appliance on patients
19.
20.
21.
ERRATUMAslan BI, Kucukkaraca E, Turkoz C, Dincer M. Treatment effects of the Forsus fatigue resistant
device used with miniscrew anchorage. Angle Orthod. 2014;84:7687. Page 76 of the article states that The FRD
is a three-piece, telescoping system incorporating a superelastic nickel-titanium coil spring The spring is actually
a stainless steel coil spring. We apologize for the error.
383